PRTK

PRTK

Last Updated:

Q3 '20

Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris.

Cash

$149.5M

Burn Rate (Qtr)

$20.9M

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Omadacycline (Nuzyra)

Acute bacterial skin and skin structure infections (ABSSSI) - IV + Oral

Approved

Q1 '20

Omadacycline (Nuzyra)

Acute bacterial skin and skin structure infections (ABSSSI) - IV Only

Approved

Q1 '20

Sarecycline (Seysara)

Inflammatory Acne (Acne Vulgaris)

Approved

Q1 '21

Omadacycline (Nuzyra)

Community acquired bacterial pneumonia (CABP) - IV + Oral

Approved

Q1 '21

Omadacycline (Nuzyra)

Community acquired bacterial pneumonia (CABP) - IV Only

sNDA Filing Submitted July 2020

Q1 '21

Omadacycline (Nuzyra)

Non-Tuberculous Mycobacteria (NTM)

Phase 2 Waiting Initiation

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon